Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs.
Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up
Cancer diagnosis firm Grail could be re-joining Illumina, the company it was spun out of in 2016, despite filing for an initial public offering (IPO) just a few days ago.
Gilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer blockbuster Trodelvy, days before survival data is due to be reveal
Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs.